Latest Tax Rebates News

Bass Oil reported a 2% rise in November oil production alongside a new gas sales agreement with Origin Energy, setting the stage for first gas sales in 2026. Indonesian operations also advanced with production enhancements and upcoming drilling plans.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Livium Ltd has secured a A$663,000 R&D tax rebate for its subsidiary VSPC, pushing total FY25 rebates to A$1.4 million and reinforcing its push into advanced battery materials and recycling.

Wide Open Agriculture has received a $586,624 tax rebate for its overseas research activities in Germany, supporting the commercialisation of its proprietary lupin protein products.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.

Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

Volt Group Limited has reported a record year-to-date revenue of $4.01 million for Q3 FY25, driven by strong sales in its Wescone and EcoQuip divisions, alongside advancing its ATEN Waste Heat to Power project.